secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tarsus Pharmaceuticals, Inc. (TARS)
CIK:        0001819790
Form:       8-K
Filed at:   2026-08-06T11:08:34+00:00
Accession:  0001819790-26-000060
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tarsus to acquire Alkeus for $450M upfront; adds Phase 3 Stargardt drug gildeuretinol
--------------------------------------------------------------------------------

- Upfront consideration: $270M cash + $180M in Tarsus stock ($61.38/share); total ~$450M.
- Milestones up to $350M (regulatory approval + first commercial sale) plus low-single-digit royalties.
- Gildeuretinol (ALK-001) is a once-daily oral for Stargardt disease; no FDA-approved therapy exists.
- Phase 3 NORTHSTAR trial enrolling ~230 patients; topline data expected H2 2029.
- Deal approved by both boards; expected to close in 2026, subject to HSR clearance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819790/000181979026000060/0001819790-26-000060-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819790/000181979026000060/tars-20260731.htm
  HTML page:      https://secwatch.observer/filing/0001819790-26-000060

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer